Massachusetts General Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Massachusetts General Hospital sits in the top decile of US sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count).
Massachusetts General Hospital: 2,032 sponsored US clinical trials, 336 recruiting.
Massachusetts General Hospital sponsors 2,032 registered US clinical trials on ClinicalTrials.gov, 336 of them currently recruiting, and 1,284 completed. 240 of these trials are in Phase 3-4 (later-stage) and 515 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 29 trials.
Top-decile sponsor footprint
Massachusetts General Hospital ranks in the top decile of sponsors by registered trial count (#4 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
2,032 total, page 30 of 41
Integrated Treatment for Smoking Cessation & Anxiety in People With HIV
NCT01393301
The Effect of Oxytocin on Fear Memory Consolidation Novel Intervention to Prevent Posttraumatic Stress Disorder (PTSD)
NCT01466127
Safety Study of Continuous Positive Airway Pressure Via a Nasal Mask
NCT01524614
Development and Testing of Adolescent Twelve-Step Facilitation
NCT01449981
HIV Prevention and Trauma Treatment for Men Who Have Sex With Men With Childhood Sexual Abuse Histories
NCT01395979
IGF-1 and Bone Loss in Women With Anorexia Nervosa
NCT01406444
Testosterone and Alendronate in Hypogonadal Men
NCT01460654
Growth Hormone Treatment on Phosphocreatine Recovery in Obesity
NCT01421589
Safety of Lactobacillus Rhamnosus GG Vs. Placebo in Elderly Subjects Receiving Trivalent Inactivated Influenza Vaccine
NCT01368029
Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling
NCT01438073
A New Micrografting Technique for Vitiligo
NCT01262547
Secondary Intention Wound Healing Versus Micrografting in Patients Undergoing Mohs Surgery
NCT01442844
Proton Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer
NCT01525446
Olfactory Deficits in Neurologic Disease
NCT05019014
Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant
NCT01398501
Nilotinib With Radiation for High Risk Chordoma
NCT01407198
Cognitive-Behavioral Therapy and Supportive Psychotherapy for Body Dysmorphic Disorder
NCT01453439
Midostaurin (PKC412) for Locally Advanced Rectal Cancer
NCT01282502
Non-Invasive Imaging for Cording in Breast Cancer Patients
NCT01427166
Natural History of Hopelessness, Suicidality, and Optimism in Psychiatric Inpatients Following Discharge
NCT01599247
Optimizing Tattoo Removal: a Side-by-side Comparison in the Search for One Treatment Tattoo Removal
NCT01624688
2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD
NCT01404208
Population-Based Patient-Centric Care: Comprehensive Preventive Cancer Screening Using Health IT
NCT01372527
Neuromonitoring During the Latarjet Procedure
NCT01621126
Study of Probiotic GanedenBC30 for Irritable Bowel Syndrome and Major Depressive Disorder
NCT01337609
Panobinostat With Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
NCT01282476
Development of a Positive Psychology Intervention to Reduce Suicide Risk
NCT01398891
Cognitive Remediation With D-Cycloserine
NCT01399866
Comparative Effectiveness Research for Eliminating Disparities
NCT02027636
Optimal Dose of Succinylcholine and Rocuronium for Electroconvulsive Therapy (ECT)
NCT01441960
Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies
NCT01401907
Evaluating Tumor Pseudoprogression With FLT-PET and MRI
NCT01105988
Brain Genomics Superstruct Project
NCT01552460
Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer
NCT01347788
Bosutinib in Adult Patients With Recurrent Glioblastoma
NCT01331291
Attentional Bias in Body Dysmorphic Disorder
NCT01398904
Laparoscopy-Assisted Transanal Endoscopy Rectosigmoid Resection for Rectal Cancer
NCT01340755
Quantification of Outcome Measures for Mind-body Interventions
NCT01308970
A Pilot Study to Test the Safety and Feasibility of a Brillouin Ocular Analyzer
NCT01775007
Oral Peanut Immunotherapy
NCT01324401
Brain Activity Flow Patterns Analysis Using Evoked Response Potentials in Youth With ADHD, Bipolar Disorder, or Autism Spectrum Disorders: A Preliminary Study
NCT01506232
Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation
NCT01288235
Understanding Mechanisms of Acquired Resistance to BIBW2992
NCT01074177
Effects of Anorexia Nervosa on Peak Bone Mass
NCT01301183
Effect of Growth Hormone (GH) on Cardiac Echos in GH Deficient Patients After Acromegaly Treatment
NCT01302652
Defining 31Phosphorous Magnetic Resonance Spectroscopy Characteristics in Patients With Mitochondrial Myopathy
NCT01301235
Predictors of the Ability to Protect the Airway in Long-term Ventilated Patients
NCT01618240
Transcutaneous Immunization With an Attenuated Listeria Monocytogenes Vector Vaccine
NCT01311817
Clinical Study to Evaluate the Effect of pH on Pain Upon Local Anesthetic Administration.
NCT01304082
Risks for Insulin Resistance and Metabolic Syndrome Between Major Depressive Disorder (MDD) or MDD With Psychotic Features
NCT01310140
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 226 |
| Phase 2 | 289 |
| Phase 3 | 58 |
| Phase 4 | 182 |
Therapeutic Areas
What is open in the Massachusetts General Hospital pipeline
336 recruiting of 2,032 indexed (17% open); 1,284 completed (63%).
Phase mix: 240 late (III/IV) vs 515 early (I/II) (early-phase heavy).
Top condition: Depression (29 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.